MedTrace Logo

Effect of Biological Disease Modifying Anti Rheumatic Drug (bDMARD) Treatment on Spinal Fracture Incidence in Patients With Ankylosing Spondylitis (AS)

NCT02840695 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 9858

Last updated 2017-10-30

No results posted yet for this study

Summary

Ankylosing spondylitis (AS) is a rheumatoid disease affecting all segments of the axial skeleton, leading to the complete fusion of all spinal segments - the bamboo-spine. During the last decade biological disease modifying anti-rheumatic drugs (bDMARD) have been successfully introduced to reduce the disease activity. It is unclear whether bDMARD treatment had an effect on spinal fracture risk related to AS. This national registry study will investigate the effect of bDMARD treatment on spinal fracture risk in a national cohort of patients with AS.

Conditions

Interventions

DRUG

bDMARD treatment

Treatment with bDMARD includes registered ATC-codes: L04AA and L04AB.

Sponsors & Collaborators

  • Uppsala University

    lead OTHER

Eligibility

Min Age
30 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2015-12-31
Completion
2017-10-24

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02840695 on ClinicalTrials.gov